Background: Anticancer drugs are often expensive and are contributing to the growing cost of cancer care. Concerns have been raised about the effect rising costs may have on availability of new anticancer drugs. Aim: This study aims to determine the recent changes in the costs of anticancer drugs in Australia. Methods: Publicly available expenditure and prices paid by the Australian Pharmaceutical Benefits Scheme (PBS) for anticancer drugs from 2000 to 2012 were reviewed. The measures used to determine changes in cost were total PBS expenditure and average price paid by the PBS per prescription for anticancer drugs and for all PBS listed drugs. An estimated monthly price paid for newly listed anticancer drugs was also calculated. Results: Annual PBS expenditure on anticancer drugs rose from A$65 million in 1999-2000 to A$466 million in 2011-2012; an average increase of 19% per annum. The average price paid by the PBS per anticancer drug prescription, adjusted for inflation, increased 133% from A$337 to A$786. The real average annual increase in the price per anticancer drug prescription was more than double that for all other PBS drugs combined (7.6% vs 2.8%, difference 4.8%, 95% confidence interval -0.4% to 10.1%, P = 0.07). The median price for a month's treatment of the new anticancer drugs listed was A$4919 (range A$1003 to A$12578, 2012 prices). Conclusions: PBS expenditure and the price of anticancer drugs in Australia rose substantially from 2000 to 2012. Dealing with these burgeoning costs will be a major challenge for our health system and for those affected by cancer. 2014 Royal Australasian College of Physicians.
Introduction
The cost of health care is rapidly rising. Health spending in Australia in recent years has increased at a faster rate than spending on all other goods and services. 1 This increase in costs creates major challenges for health care systems, particularly those like Australia's that are publically funded.
The cost of cancer care has more than doubled over the past 20 years with a most recent estimate of over $5 billion per year in 2009. 2 The causes are complex and include the growing availability and use of new and expensive anticancer drugs. 3 Spending on drugs is one of the fastest growing components of health care costs in developed countries. 1 Anticancer drugs are estimated to represent 10% of cancer costs in OECD countries. 4 Concerns have been raised about the effects of rising prices on the availability of new anticancer drugs. 4, 5, 6 In Australia, widespread access to expensive drugs depends on whether they are listed on the Pharmaceutical Benefits Scheme (PBS). PBS listing requires a favourable assessment of costeffectiveness which is not forthcoming for every effective anticancer drug. Gaining access to effective anticancer drugs that are not listed on the PBS is a major dilemma for patients and doctors.
However, we were unable to find published reports focusing on the costs of anticancer drugs in Australia that might inform clinicians and patients facing this increasingly common challenge.
The aims of this study were to 1) determine changes in PBS expenditure on anticancer drugs from 2000 to 2012; 2) compare price increases for anticancer drugs to other drugs listed on the PBS; 3) determine the monthly price paid for newly listed anticancer drugs; and, 4) consider the reasons for, and implications of, our findings.
PBS expenditure and average prescription prices
We determined annual expenditure and prescription volumes for all PBS listed drugs, and for anticancer drugs (using the PBS subcategory Anti-neoplastics), from the publicly available
Pharmaceutical Benefits Pricing Authority Annual Reports (2000-2010) and Pharmaceutical Benefits
Scheme Expenditure and Prescription reports (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . 7, 8 The average price paid by the PBS per prescription was calculated by dividing the total expenditure by prescription volumes for each year.
Patient co-payments were not included in these calculations. All prices were adjusted to reflect 2012 values ("real" prices) using the average health prices inflation figure of 3.0% from 1999-2000 to 2010-2011.
1, 9
Monthly prices of newly listed anticancer drugs PBS schedules from January 2000 to June 2012 were searched for listings of new anticancer drugs that were categorised under the PBS subcategory Anti-neoplastics. 10 Drugs that were listed on the PBS prior to 2000 but granted additional indications from 2000 to 2012 were not included. Prices paid by the PBS for a month's treatment (28 days) were calculated for each new anticancer drug using the recommended schedule and 'typical' dose calculated for a patient with body surface area (1.73m 2 ) and/or body weight (70kg). 11 If a drug dose varied during a treatment protocol then the dose used for the majority of the protocol was chosen for the typical dose calculation.
For each new anticancer drug listed, the dispensed price for maximum quantity was determined from the PBS schedule in the year the drug was listed. 10 An approximation of the price paid by the PBS for each dose was determined by calculating the proportion of the maximum quantity required for a typical dose. For intravenous drugs, we determined the price using the most efficient combination of vials required for the typical dose. The estimated price paid per month was determined by multiplying the price per dose by the number of doses required per month.
We did not consider anticancer drugs listed under subcategories other than Anti-neoplastics, for example, endocrine therapies, vaccines, supportive care drugs, and drugs for non-melanoma skin cancer.
Statistical analysis
Descriptive statistics were used to analyse the monthly prices of new drugs listed on the PBS. A paired t-test was used to compare the annual average price rise in anticancer drugs to the annual average price rise for all other PBS listed drugs combined. Data was analysed with SPSS version 20. terms, climbing an average of 7.6% per annum, which echo US price rises over a similar period. 13 In comparison, the average price paid by the PBS for all other PBS drugs combined has increased more gradually.
Results

PBS
The many and complex reasons for the rise in PBS expenditure on anticancer drugs include increases in the prevalence of cancer and in the proportions of patients for whom there are suitable treatments. 14 The 7.6% rise per annum in the average price paid by the PBS per prescription for anticancer drugs is driven by rapid growth in the number of new expensive drugs. This may explain why the average prices paid for prescriptions used to treat other high burden diseases, in which the number of newly available drugs has grown more slowly, have changed much less. For example for drugs used to treat diabetes, the average annual increase in the average prescription price paid by the PBS over the study period was 1.6%, while for lipid-modifying drugs and psychoanaleptics used to treat mental illness, there have been average annual falls of 2.4% and 2.0% respectively.
7, 8
The effort to develop newer and better drugs to treat patients with cancer has resulted in over 70
anticancer drugs being currently listed on the PBS, many with multiple indications. 10 The US Food and Drug Administration approved 12 new anticancer drugs in 2012 alone. 15 Some have argued that the price of new anticancer drugs is increasing rapidly because of the increasing cost of drug development , with estimates ranging from $500 million to $2 billion per new drug approved. 16 This figure includes substantial expenditure on drugs that fail to reach the market. For example, it is estimated that of the 920 drugs tested in clinical trials between 1990 and 2006, only 32 were approved in the US. 17 Debate continues about whether these costs justify the asking price for new anticancer drugs, particularly when marketing budgets and profits are also substantial. 15 Many new anticancer drugs are molecularly-targeted and are substantially more expensive than traditional cytotoxic drugs. 12 The beneficial effects of targeted anticancer drugs are usually confined to a subgroup of all patients. The presence of a testable molecular target offers the potential to identify and treat only those for whom treatment is most likely to be beneficial. This reduces the total number of patients to be treated, which should reduce total costs, but also provides a commercial rationale for increasing the price to make up for a smaller market. Another factor tending to increase the total costs of molecularly targeted agents is that they are often used for longer periods than their cytotoxic counterparts. 18 Furthermore, older anticancer drugs are commonly not phased out with the introduction of new drugs but rather used sequentially or in combination which also significantly contributes to growing costs. 19 Reductions in prices of anticancer drugs due to the availability of generic equivalents can help mitigate the effect of expensive new drugs on the growth rate of expenditure. Australia's pricing and reimbursement system may result in a lower price for new drugs, but a higher price for generic drugs, in comparison with similarly developed countries. 20 Therefore, the potential cost savings due to the use of generic drugs may not be as substantial in Australia as in other developed countries, an Despite rapid rises in total expenditure on anticancer drugs, and in the average price paid by the PBS per prescription, anticancer drugs accounted for less than 6% of the total PBS budget in 2012.
Anticancer drugs are estimated to account for about 10-15% of expenditure on cancer care; hospitalisation of cancer patients is estimated to account for about 70%. 23 Nevertheless, the rising costs of anticancer drugs substantially strains publicly funded health care systems like Australia's.
The Pharmaceutical Benefits Advisory Committee (PBAC), the body that makes recommendations to the Federal health minister as to whether new drugs should be publically reimbursed, is just as likely to make a positive recommendation for an anticancer drug as it is for other drugs. 24 Despite this, the high price asked for many new anticancer drugs often results in an initial rejection for PBS listing due to the PBAC's reasonable assessment of unsatisfactory cost-effectiveness. This delays, and therefore reduces access to reimbursed new anticancer drugs.
This study indicates that patients wanting to use new anticancer drugs that are not reimbursed currently face bills of about $5000 per month. Physicians will increasingly find themselves in the difficult position of having to discuss with patients whether the financial toxicity of these new drugs is warranted by their benefits, which are often relatively modest. 25 This study demonstrates a substantial increase in the average prescription price paid by the PBS for anticancer drugs, over and above inflation for health prices in general, alongside a rapid growth in total government expenditure on anticancer drugs. Dealing with these burgeoning costs at both the societal level, and for individuals, while retaining effective, equitable and readily accessible cancer care, poses a major challenge for all health systems. (17) 3 (13) 3 (13) 3 (13) 3 (13) 7 (30) 
